Met Life Investment Management, LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Met Life Investment Management, LLC

$17.1 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$38.96 - $42.75 $1.25 Million - $1.37 Million	-32,096 Reduced 87.87%	4,432 $181,000
Q1 2024 May 14, 2024	BUY	$40.88 - $43.27 $1.49 Million - $1.58 Million	36,528 New	36,528 $1.54 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $80,998 - $169,590	3,996 Added 12.19%	36,782 $1.56 Million
Q3 2023 May 09, 2024	BUY	$20.26 - $31.91 $47,955 - $75,530	2,367 Added 7.78%	32,786 $715,000
Q2 2023 Apr 29, 2024	BUY	$23.9 - $35.38 $783,585 - $1.16 Million	32,786 New	32,786 $1.04 Million
Q2 2023 Aug 10, 2023	BUY	$23.9 - $35.38 $56,571 - $83,744	2,367 Added 7.78%	32,786 $1.04 Million
Q1 2023 May 09, 2024	BUY	$22.82 - $35.32 $694,161 - $1.07 Million	30,419 New	30,419 $742 Million
Q4 2022 May 10, 2024	BUY	$25.35 - $31.96 $40,002 - $50,432	1,578 Added 5.47%	30,419 $959,000
Q4 2022 Mar 22, 2023	BUY	$25.35 - $31.96 $40,002 - $50,432	1,578 Added 5.47%	30,419 $959,000
Q4 2022 Feb 15, 2023	BUY	$25.35 - $31.96 $40,002 - $50,432	1,578 Added 5.47%	30,419 $959,000
Q3 2022 Jun 14, 2023	SELL	$25.5 - $41.42 $40,239 - $65,360	-1,578 Reduced 5.19%	28,841 $815,000
Q2 2022 May 10, 2024	BUY	$20.62 - $37.15 $75,943 - $136,823	3,683 Added 14.64%	28,841 $762,000
Q2 2022 Jun 20, 2023	SELL	$20.62 - $37.15 $32,538 - $58,622	-1,578 Reduced 5.19%	28,841 $762,000
Q2 2022 Mar 22, 2023	BUY	$20.62 - $37.15 $75,943 - $136,823	3,683 Added 14.64%	28,841 $762,000
Q2 2022 Aug 11, 2022	BUY	$20.62 - $37.15 $75,943 - $136,823	3,683 Added 14.64%	28,841 $763,000
Q1 2022 May 10, 2024	BUY	$23.5 - $35.38 $591,213 - $890,090	25,158 New	25,158 $880,000
Q1 2022 Jun 20, 2023	SELL	$23.5 - $35.38 $123,633 - $186,134	-5,261 Reduced 17.3%	25,158 $880,000
Q1 2022 Mar 22, 2023	BUY	$23.5 - $35.38 $218,197 - $328,503	9,285 Added 58.5%	25,158 $880,000
Q1 2022 May 12, 2022	BUY	$23.5 - $35.38 $218,197 - $328,503	9,285 Added 58.5%	25,158 $881,000
Q4 2021 Jun 21, 2023	SELL	$29.21 - $44.64 $424,888 - $649,333	-14,546 Reduced 47.82%	15,873 $514,000
Q3 2021 Jun 21, 2023	SELL	$21.26 - $38.85 $309,247 - $565,112	-14,546 Reduced 47.82%	15,873 $468,000
Q2 2021 May 17, 2024	SELL	$12.56 - $29.69 $259,426 - $613,246	-20,655 Reduced 56.55%	15,873 $406,000
Q2 2021 Jun 21, 2023	SELL	$12.56 - $29.69 $182,697 - $431,870	-14,546 Reduced 47.82%	15,873 $406,000
Q2 2021 Mar 22, 2023	SELL	$12.56 - $29.69 $182,697 - $431,870	-14,546 Reduced 47.82%	15,873 $406,000
Q2 2021 Aug 16, 2021	BUY	$12.56 - $29.69 $199,364 - $471,269	15,873 New	15,873 $407,000

Others Institutions Holding CERE

# of Institutions

Shares Held

5.01M

Call Options Held

3.3K

Put Options Held

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account